Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Entera Bio Ltd.
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Tickers
ENTX
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 08, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Tickers
ENTX
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Tickers
ENTX
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 02, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Tickers
ENTX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.